S. Antoni, Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends, Eur. Urol, vol.71, pp.96-108, 2017.

, Survival Rates for Bladder Cancer

, Cancer Stat Facts: Bladder Cancer

H. Maase and . Der, Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer, J. Clin. Oncol, vol.23, pp.4602-4608, 2005.

M. De-santis, Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986, J. Clin. Oncol, vol.30, pp.191-199, 2012.

D. M. Pardoll, The blockade of immune checkpoints in cancer immunotherapy, Nat. Rev. Cancer, vol.12, pp.252-264, 2012.

Y. Ning, FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy, The oncologist, vol.22, pp.743-749, 2017.

J. Brahmer, Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-SmallCell Lung Cancer, N. Engl. J. Med, vol.373, pp.123-135, 2015.

M. Reck, Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-SmallCell Lung Cancer, N. Engl. J. Med, vol.375, pp.1823-1833, 2016.

J. Bellmunt, Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma, N. Engl. J. Med, vol.376, pp.1015-1026, 2017.

T. Powles, Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, openlabel, phase 3 randomised controlled trial, Lancet, vol.391, pp.748-757, 2018.

E. Pons-tostivint, Comparative analysis of durable responders on immune checkpoint inhibitors (ICI) versus other systemic therapies: A meta-analysis of phase III trials, J. Clin. Oncol, vol.36, pp.3070-3070, 2018.

E. Borcoman, A. Nandikolla, G. Long, S. Goel, and C. Le-tourneau, Patterns of Response and Progression to Immunotherapy, Am. Soc. Clin. Oncol. Educ. Book Am. Soc

, Clin. Oncol. Annu. Meet, pp.169-178, 2018.

R. Bruno, F. Mercier, and L. Claret, Evaluation of tumor size response metrics to predict survival in oncology clinical trials, Clin. Pharmacol. Ther, vol.95, pp.386-393, 2014.

L. Claret, A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor Kinetics, Clin. Cancer Res, vol.24, pp.3292-3298, 2018.

Y. Zheng, Population Modeling of Tumor Kinetics and Overall Survival to Identify Prognostic and Predictive Biomarkers of Efficacy for Durvalumab in Patients With Urothelial Carcinoma, Clin. Pharmacol. Ther, vol.103, pp.643-652, 2018.

J. G. Ibrahim, H. Chu, and L. M. Chen, Basic concepts and methods for joint models of longitudinal and survival data, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.28, pp.2796-2801, 2010.

D. Rizopoulos, Joint Models for Longitudinal and Time-to-Event Data

D. Rizopoulos, Dynamic predictions and prospective accuracy in joint models for longitudinal and time-to-event data, Biometrics, vol.67, pp.819-829, 2011.

C. Mbogning, K. Bleakley, and M. Lavielle, Joint modelling of longitudinal and repeated time-to-event data using nonlinear mixed-effects models and the stochastic approximation expectation-maximization algorithm, J. Stat. Comput. Simul, vol.85, pp.1512-1528, 2015.

L. Wu, W. Liu, G. Y. Yi, and Y. Huang, Analysis of Longitudinal and Survival Data: Joint Modeling, Inference Methods, and Issues, J. Probab. Stat, 2012.

M. Sène, C. Bellera, and C. Proust-lima, Shared random-effect models for the joint analysis of longitudinal and time-to-event data: application to the prediction of prostate cancer recurrence, 2013.

L. Claret, Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer, J. Clin. Oncol, vol.31, pp.2110-2114, 2013.

A. A. Tsiatis, V. Degruttola, and M. S. Wulfsohn, Modeling the Relationship of Survival to Longitudinal Data Measured with Error. Applications to Survival and CD4 Counts in Patients with, AIDS. J. Am. Stat. Assoc, vol.90, pp.27-37, 1995.

S. Desmée, F. Mentré, C. Veyrat-follet, and J. Guedj, Nonlinear Mixed-effect Models for Prostate-specific Antigen Kinetics and Link with Survival in the Context of Metastatic Prostate Cancer: A Comparison by Simulation of Two-stage and Joint Approaches, AAPS J, vol.17, pp.691-699, 2015.

W. D. Stein, Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy

, Clin. Cancer Res, vol.17, pp.907-917, 2011.

J. L. Gulley, Immunotherapy biomarkers 2016: overcoming the barriers, J. Immunother. Cancer, 2017.

S. Desmée, F. Mentré, C. Veyrat-follet, B. Sébastien, and J. Guedj, Nonlinear joint models for individual dynamic prediction of risk of death using Hamiltonian Monte Carlo: application to metastatic prostate cancer, BMC Med. Res. Methodol, 2017.

E. Andrinopoulou, Dynamic prediction of outcome for patients with severe aortic stenosis: application of joint models for longitudinal and time-to-event data, BMC Cardiovasc. Disord, 2015.

L. Li, S. Luo, B. Hu, and T. Greene, Dynamic Prediction of Renal Failure Using Longitudinal Biomarkers in a Cohort Study of Chronic Kidney Disease, Stat. Biosci, vol.9, pp.357-378, 2017.

J. Wang, S. Luo, and L. Li, Dynamic prediction for multiple repeated measures and event time data: an application to Parkinson's disease, Ann. Appl. Stat, vol.11, pp.1787-1809, 2017.

D. C. Turner, Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.24, pp.5841-5849, 2018.

R. Bruno, A tumor growth inhibition-overall survival model to assess exposure response and support dose justification of atezolizumab, a PD-L1 inhibitor

I. Netterberg, A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab-Treated non-small Cell Lung Cancer Patients, Clin. Pharmacol. Ther, 2018.

J. E. Rosenberg, Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial, Lancet, vol.387, pp.1909-1920, 2016.

E. A. Eisenhauer, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur. J. Cancer, vol.228, p.247, 2009.

M. Lavielle, Mixed Effects Models for the Population Approach : Models, Tasks, Methods and Tools
URL : https://hal.archives-ouvertes.fr/hal-01122873

B. Delyon, M. Lavielle, and E. Moulines, Convergence of a stochastic approximation version of the EM algorithm, Ann Stat, vol.27, pp.94-128, 1999.

E. Kuhn and M. Lavielle, Maximum likelihood estimation in nonlinear mixed effects models, Comput. Stat. Data Anal, vol.49, pp.1020-1038, 2005.

T. H. Nguyen, Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics, CPT Pharmacomet. Syst. Pharmacol, vol.6, pp.87-109, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01484967

M. Cerou, M. Lavielle, K. Brendel, M. Chenel, and E. Comets, Development and performance of npde for the evaluation of time-to-event models, Pharm. Res, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-01695500

T. A. Gerds, T. Cai, and M. Schumacher, The performance of risk prediction models, Biom. J. Biom. Z, vol.50, pp.457-479, 2008.

P. J. Heagerty, T. Lumley, and M. S. Pepe, Time-dependent ROC curves for censored survival data and a diagnostic marker, Biometrics, vol.56, pp.337-344, 2000.

T. A. Gerds and M. Schumacher, Consistent estimation of the expected Brier score in general survival models with right-censored event times, Biom. J. Biom. Z, vol.48, pp.1029-1040, 2006.

P. Blanche, J. Dartigues, and H. Jacqmin-gadda, Review and comparison of ROC curve estimators for a time-dependent outcome with marker-dependent censoring

, J. Biom. Z, vol.55, pp.687-704, 2013.